Sponsored by the HealthcareTrainingInstitute.org providing Quality Education since 1979
Add to Shopping Cart

HIV: Therapeutic Strategies for Guilt, Uncertainty, and Taking Control
6 CEUs Cultural Diversity & Ethical Boundaries: Freedom from Stereotypes

Section 18
State HIV Prevention Progress Report 2014

CEU Answer Booklet | Table of Contents | HIV/AIDS CEU Courses
Counselor CEUs, Social Worker CEUs, Psychologist CEs, MFT CEUs 


The Flip Book below is from Centers for Disease Control and Prevention 

Hint:
1. Use + and – at top of page to increase or decrease size
2. Click and drag on page to move text to be more visible , if needed
3. Click speaker at top of page to add or delete sound
4. If message below indicates "A plugin is needed to display this content." CLICK HERE
Questions? Email: [email protected]

- Dietz, Patricia M. ,DrPH, Amy L. Krueger, MPH, Richard J. Wolitski, PhD, Anna Satcher Johnson, MPH, Erica Dunbar, MPH, Lillian S. Lin, PhD, Samuel Dooley, MD, Donna Hubbard McCree, PhD, Shubha Rao, MPH, H. Irene Hall, PhD Dale Stratford, PhD, State HIV Prevention Progress Report 2014, Centers for Disease Control and Prevention 2014, p1-108.


 
Others who bought this HIV/AIDS Course
also bought…

Scroll DownScroll UpCourse Listing Bottom Cap

CEU Answer Booklet for this course | HIV/AIDS CEU Courses
Forward to Section 19
Back to Section 17
Table of Contents
Top

The article above contains foundational information. Articles below contain optional updates.
Switching to TAF-based PrEP improves kidney and bone markers – but does it raise cardiovascular risk?
People who switched from Truvada (tenofovir disoproxil fumarate/emtricitabine) to the newer Descovy (tenofovir alafenamide/emtricitabine) for pre-exposure prophylaxis (PrEP) experienced improvements in measures of kidney function and bone density, but adverse clinical outcomes were rare with either coformulation, researchers reported at the recent IDWeek 2019 conference in Washington, DC.
Oral cabotegravir and rilpivirine still effective at 312 weeks
A combination of two once-daily oral antiretrovirals, cabotegravir and rilpivirine, maintained HIV suppression for 5.5 years after a six-month lead-in period, according to a presentation at the recent IDWeek 2019 conference in Washington, DC.
High levels of engagement in care by children and young people with HIV in the UK and Ireland
There are good results for the paediatric cascade of care in the UK and Ireland, researchers report in the Journal of the International AIDS Society. Almost all young people have some engagement with care, 92% are taking HIV treatment and 86% are virologically suppressed. The uptake of treatment increased between 2010 and 2016, but the proportion who are virologically suppressed did not.
Rapid treatment start doesn't benefit all
People who started HIV treatment in the first few weeks after being diagnosed with HIV were significantly less likely to be retained in care a year later, a large French study has reported. French researchers associated with the Dat’AIDS study group, reporting their analysis in the journal PLOS ONE, say that measures to speed up treatment initiation are not benefitting all people.
Ibalizumab monoclonal antibody is effective in real-world use
Ibalizumab (Trogarzo), a long-acting monoclonal antibody that prevents HIV from entering cells, suppressed HIV for 48 weeks in people with highly resistant virus who received the drug in an expanded access programme, according to a presentation at the IDWeek 2019 conference in Washington, DC.

CEU Continuing Education for
Social Work CEUs, Psychology CEUs, Counselor CEUs, MFT CEUs

 


OnlineCEUcredit.com Login


Forget your Password Reset it!